Weighted Average Number of Shares Outstanding, Basic of KalVista Pharmaceuticals, Inc. from 30 Apr 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
KalVista Pharmaceuticals, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Apr 2020 to 30 Sep 2025.
  • KalVista Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Sep 2025 was 53,883,681, a 16% increase year-over-year.
  • KalVista Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 49,652,878, a 35% increase from 2023.
  • KalVista Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 36,786,575, a 32% increase from 2022.
  • KalVista Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 27,890,846, a 14% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 53,883,681 +7,293,527 +16% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 53,497,128 +7,264,151 +16% 01 May 2025 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q1 2025 49,652,878 +12,866,303 +35% 01 Feb 2025 30 Apr 2025 10-K 10 Jul 2025 2025 FY
Q4 2024 52,638,888 +17,915,509 +52% 01 Nov 2024 31 Jan 2025 10-Q 12 Mar 2025 2025 Q3
Q3 2024 46,590,154 +12,024,199 +35% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 46,232,977 +11,818,751 +34% 01 May 2024 31 Jul 2024 10-Q 11 Sep 2025 2026 Q1
Q1 2024 36,786,575 +8,895,729 +32% 01 Feb 2024 30 Apr 2024 10-K 10 Jul 2025 2025 FY
Q4 2023 34,723,379 +6,444,926 +23% 01 Nov 2023 31 Jan 2024 10-Q 12 Mar 2025 2025 Q3
Q3 2023 34,565,955 +9,970,916 +41% 01 Aug 2023 31 Oct 2023 10-Q 05 Dec 2024 2025 Q2
Q2 2023 34,414,226 +9,856,611 +40% 01 May 2023 31 Jul 2023 10-Q 05 Sep 2024 2025 Q1
Q1 2023 27,890,846 +3,417,754 +14% 01 Feb 2023 30 Apr 2023 10-K 11 Jul 2024 2024 FY
Q4 2022 28,278,453 +3,798,793 +16% 01 Nov 2022 31 Jan 2023 10-Q 11 Mar 2024 2024 Q3
Q3 2022 24,595,039 +155,416 +0.64% 01 Aug 2022 31 Oct 2022 10-Q 07 Dec 2023 2024 Q2
Q2 2022 24,557,615 +127,696 +0.52% 01 May 2022 31 Jul 2022 10-Q 07 Sep 2023 2024 Q1
Q1 2022 24,473,092 01 Feb 2022 30 Apr 2022 10-K 11 Jul 2024 2024 FY
Q4 2021 24,479,660 01 Nov 2021 31 Jan 2022 10-Q 09 Mar 2023 2023 Q3
Q3 2021 24,439,623 01 Aug 2021 31 Oct 2021 10-Q 08 Dec 2022 2023 Q2
Q2 2021 24,429,919 01 May 2021 31 Jul 2021 10-Q 08 Sep 2022 2023 Q1

KalVista Pharmaceuticals, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 49,652,878 +12,866,303 +35% 01 May 2024 30 Apr 2025 10-K 10 Jul 2025 2025 FY
2023 36,786,575 +8,895,729 +32% 01 May 2023 30 Apr 2024 10-K 10 Jul 2025 2025 FY
2022 27,890,846 +3,417,754 +14% 01 May 2022 30 Apr 2023 10-K 11 Jul 2024 2024 FY
2021 24,473,092 +5,378,652 +28% 01 May 2021 30 Apr 2022 10-K 11 Jul 2024 2024 FY
2020 19,094,440 +1,345,774 +7.6% 01 May 2020 30 Apr 2021 10-K 10 Jul 2023 2023 FY
2019 17,748,666 01 May 2019 30 Apr 2020 10-K 07 Jul 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.